Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.
Identifieur interne : 000970 ( Main/Exploration ); précédent : 000969; suivant : 000971Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.
Auteurs : Joseph A. Paladino [États-Unis] ; David M. Jacobs [États-Unis] ; Ryan K. Shields [États-Unis] ; Jerusha Taylor [États-Unis] ; Justin Bader [États-Unis] ; Martin H. Adelman [États-Unis] ; Greg J. Wilton [États-Unis] ; John K. Crane [États-Unis] ; Jerome J. Schentag [États-Unis]Source :
- International journal of antimicrobial agents [ 1872-7913 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Antibactériens (usage thérapeutique), Bactériémie (), Bactériémie (microbiologie), Bactériémie (traitement médicamenteux), Céphalosporines (usage thérapeutique), Démographie, Facteurs temps, Femelle, Glycopeptides (usage thérapeutique), Humains, Infections à staphylocoques (), Infections à staphylocoques (microbiologie), Infections à staphylocoques (traitement médicamenteux), Mâle, Staphylococcus aureus résistant à la méticilline (), Sujet âgé, Sujet âgé de 80 ans ou plus, Tests de sensibilité microbienne, Vancomycine (usage thérapeutique), Échec thérapeutique, Éradication de maladie, Études cas-témoins, Études rétrospectives.
- MESH :
- microbiologie : Bactériémie, Infections à staphylocoques.
- traitement médicamenteux : Bactériémie, Infections à staphylocoques.
- usage thérapeutique : Antibactériens, Céphalosporines, Glycopeptides, Vancomycine.
- Adulte, Adulte d'âge moyen, Bactériémie, Démographie, Facteurs temps, Femelle, Humains, Infections à staphylocoques, Mâle, Staphylococcus aureus résistant à la méticilline, Sujet âgé, Sujet âgé de 80 ans ou plus, Tests de sensibilité microbienne, Échec thérapeutique, Éradication de maladie, Études cas-témoins, Études rétrospectives.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Anti-Bacterial Agents (therapeutic use), Bacteremia (drug therapy), Bacteremia (microbiology), Bacteremia (prevention & control), Case-Control Studies, Cephalosporins (therapeutic use), Demography, Disease Eradication, Female, Glycopeptides (therapeutic use), Humans, Male, Methicillin-Resistant Staphylococcus aureus (drug effects), Microbial Sensitivity Tests, Middle Aged, Retrospective Studies, Staphylococcal Infections (drug therapy), Staphylococcal Infections (microbiology), Staphylococcal Infections (prevention & control), Time Factors, Treatment Failure, Vancomycin (therapeutic use).
- MESH :
- chemical , therapeutic use : Anti-Bacterial Agents, Cephalosporins, Glycopeptides, Vancomycin.
- drug effects : Methicillin-Resistant Staphylococcus aureus.
- drug therapy : Bacteremia, Staphylococcal Infections.
- microbiology : Bacteremia, Staphylococcal Infections.
- prevention & control : Bacteremia, Staphylococcal Infections.
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Demography, Disease Eradication, Female, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Retrospective Studies, Time Factors, Treatment Failure.
Abstract
Elevated minimum inhibitory concentrations (MICs) of vancomycin against meticillin-resistant Staphylococcus aureus (MRSA) and the emergence of heteroresistant S. aureus strains have led to increased use of anti-MRSA antibiotics other than vancomycin. Ceftaroline fosamil is a novel cephalosporin with activity against MRSA, but there are limited clinical data on its use for MRSA bacteraemia (MRSAB) and against strains exhibiting high vancomycin MICs (2-4 μg/mL). This multicentre, retrospective, case-control study compared the microbiological and clinical effectiveness of ceftaroline used after vancomycin failure with that of vancomycin-treated controls for the treatment of MRSA with vancomycin MICs ≥ 2 μg/mL. In total, 32 patients were matched 1:1 with respect to vancomycin MIC, age and origin of bacteraemia. In the ceftaroline group, patients received prior MRSA therapy for a median of 5 days [interquartile range (IQR), 3-15.8 days] prior to switching to ceftaroline. Median time to eradication of MRSA was significantly less after treatment with ceftaroline compared with vancomycin [4 days (IQR, 3-7.5 days) vs. 8 days (IQR, 5.8-19.5 days); P=0.02]. Both clinical success at the end of treatment and recurrence of MRSA at Day 7 were trending towards being inferior in the vancomycin group, although the results did not attain statistical significance [81% vs. 44% (P=0.06) and 6% vs. 38% (P=0.08), respectively]. Ceftaroline added at the point of vancomycin failure resolves MRSAB more rapidly and with a higher rate of clinical success, therefore ceftaroline should be considered as an alternative for these difficult-to-treat infections.
DOI: 10.1016/j.ijantimicag.2014.07.024
PubMed: 25282169
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000C35
- to stream PubMed, to step Curation: 000C35
- to stream PubMed, to step Checkpoint: 000C35
- to stream Ncbi, to step Merge: 003872
- to stream Ncbi, to step Curation: 003872
- to stream Ncbi, to step Checkpoint: 003872
- to stream Main, to step Merge: 000975
- to stream Main, to step Curation: 000970
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.</title><author><name sortKey="Paladino, Joseph A" sort="Paladino, Joseph A" uniqKey="Paladino J" first="Joseph A" last="Paladino">Joseph A. Paladino</name><affiliation wicri:level="2"><nlm:affiliation>University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214, USA; CPL Associates, LLC, 73 High St., Buffalo, NY 14203, USA; Erie County Medical Center, 462 Grider St., Buffalo, NY 14215, USA. Electronic address: paladino@buffalo.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214, USA; CPL Associates, LLC, 73 High St., Buffalo, NY 14203, USA; Erie County Medical Center, 462 Grider St., Buffalo, NY 14215</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Jacobs, David M" sort="Jacobs, David M" uniqKey="Jacobs D" first="David M" last="Jacobs">David M. Jacobs</name><affiliation wicri:level="2"><nlm:affiliation>University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214, USA; CPL Associates, LLC, 73 High St., Buffalo, NY 14203, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214, USA; CPL Associates, LLC, 73 High St., Buffalo, NY 14203</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Shields, Ryan K" sort="Shields, Ryan K" uniqKey="Shields R" first="Ryan K" last="Shields">Ryan K. Shields</name><affiliation wicri:level="4"><nlm:affiliation>University of Pittsburgh, Department of Medicine, 3601 Fifth Ave., Falk Medical Building, Suite 3A, Pittsburgh, PA 15213, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Pittsburgh, Department of Medicine, 3601 Fifth Ave., Falk Medical Building, Suite 3A, Pittsburgh, PA 15213</wicri:regionArea><placeName><region type="state">Pennsylvanie</region><settlement type="city">Pittsburgh</settlement></placeName><orgName type="university">Université de Pittsburgh</orgName></affiliation></author><author><name sortKey="Taylor, Jerusha" sort="Taylor, Jerusha" uniqKey="Taylor J" first="Jerusha" last="Taylor">Jerusha Taylor</name><affiliation wicri:level="2"><nlm:affiliation>Oregon Health and Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Oregon Health and Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239</wicri:regionArea><placeName><region type="state">Oregon</region></placeName></affiliation></author><author><name sortKey="Bader, Justin" sort="Bader, Justin" uniqKey="Bader J" first="Justin" last="Bader">Justin Bader</name><affiliation wicri:level="2"><nlm:affiliation>University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Adelman, Martin H" sort="Adelman, Martin H" uniqKey="Adelman M" first="Martin H" last="Adelman">Martin H. Adelman</name><affiliation wicri:level="2"><nlm:affiliation>CPL Associates, LLC, 73 High St., Buffalo, NY 14203, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>CPL Associates, LLC, 73 High St., Buffalo, NY 14203</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Wilton, Greg J" sort="Wilton, Greg J" uniqKey="Wilton G" first="Greg J" last="Wilton">Greg J. Wilton</name><affiliation wicri:level="2"><nlm:affiliation>CPL Associates, LLC, 73 High St., Buffalo, NY 14203, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>CPL Associates, LLC, 73 High St., Buffalo, NY 14203</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Crane, John K" sort="Crane, John K" uniqKey="Crane J" first="John K" last="Crane">John K. Crane</name><affiliation wicri:level="2"><nlm:affiliation>Erie County Medical Center, 462 Grider St., Buffalo, NY 14215, USA; University at Buffalo School of Medicine, 326 Biomedical Research Building, 3435 Main St., Buffalo, NY 14214, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Erie County Medical Center, 462 Grider St., Buffalo, NY 14215, USA; University at Buffalo School of Medicine, 326 Biomedical Research Building, 3435 Main St., Buffalo, NY 14214</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Schentag, Jerome J" sort="Schentag, Jerome J" uniqKey="Schentag J" first="Jerome J" last="Schentag">Jerome J. Schentag</name><affiliation wicri:level="2"><nlm:affiliation>University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214, USA; CPL Associates, LLC, 73 High St., Buffalo, NY 14203, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214, USA; CPL Associates, LLC, 73 High St., Buffalo, NY 14203</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25282169</idno><idno type="pmid">25282169</idno><idno type="doi">10.1016/j.ijantimicag.2014.07.024</idno><idno type="wicri:Area/PubMed/Corpus">000C35</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C35</idno><idno type="wicri:Area/PubMed/Curation">000C35</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000C35</idno><idno type="wicri:Area/PubMed/Checkpoint">000C35</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000C35</idno><idno type="wicri:Area/Ncbi/Merge">003872</idno><idno type="wicri:Area/Ncbi/Curation">003872</idno><idno type="wicri:Area/Ncbi/Checkpoint">003872</idno><idno type="wicri:Area/Main/Merge">000975</idno><idno type="wicri:Area/Main/Curation">000970</idno><idno type="wicri:Area/Main/Exploration">000970</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.</title><author><name sortKey="Paladino, Joseph A" sort="Paladino, Joseph A" uniqKey="Paladino J" first="Joseph A" last="Paladino">Joseph A. Paladino</name><affiliation wicri:level="2"><nlm:affiliation>University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214, USA; CPL Associates, LLC, 73 High St., Buffalo, NY 14203, USA; Erie County Medical Center, 462 Grider St., Buffalo, NY 14215, USA. Electronic address: paladino@buffalo.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214, USA; CPL Associates, LLC, 73 High St., Buffalo, NY 14203, USA; Erie County Medical Center, 462 Grider St., Buffalo, NY 14215</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Jacobs, David M" sort="Jacobs, David M" uniqKey="Jacobs D" first="David M" last="Jacobs">David M. Jacobs</name><affiliation wicri:level="2"><nlm:affiliation>University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214, USA; CPL Associates, LLC, 73 High St., Buffalo, NY 14203, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214, USA; CPL Associates, LLC, 73 High St., Buffalo, NY 14203</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Shields, Ryan K" sort="Shields, Ryan K" uniqKey="Shields R" first="Ryan K" last="Shields">Ryan K. Shields</name><affiliation wicri:level="4"><nlm:affiliation>University of Pittsburgh, Department of Medicine, 3601 Fifth Ave., Falk Medical Building, Suite 3A, Pittsburgh, PA 15213, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Pittsburgh, Department of Medicine, 3601 Fifth Ave., Falk Medical Building, Suite 3A, Pittsburgh, PA 15213</wicri:regionArea><placeName><region type="state">Pennsylvanie</region><settlement type="city">Pittsburgh</settlement></placeName><orgName type="university">Université de Pittsburgh</orgName></affiliation></author><author><name sortKey="Taylor, Jerusha" sort="Taylor, Jerusha" uniqKey="Taylor J" first="Jerusha" last="Taylor">Jerusha Taylor</name><affiliation wicri:level="2"><nlm:affiliation>Oregon Health and Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Oregon Health and Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239</wicri:regionArea><placeName><region type="state">Oregon</region></placeName></affiliation></author><author><name sortKey="Bader, Justin" sort="Bader, Justin" uniqKey="Bader J" first="Justin" last="Bader">Justin Bader</name><affiliation wicri:level="2"><nlm:affiliation>University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Adelman, Martin H" sort="Adelman, Martin H" uniqKey="Adelman M" first="Martin H" last="Adelman">Martin H. Adelman</name><affiliation wicri:level="2"><nlm:affiliation>CPL Associates, LLC, 73 High St., Buffalo, NY 14203, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>CPL Associates, LLC, 73 High St., Buffalo, NY 14203</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Wilton, Greg J" sort="Wilton, Greg J" uniqKey="Wilton G" first="Greg J" last="Wilton">Greg J. Wilton</name><affiliation wicri:level="2"><nlm:affiliation>CPL Associates, LLC, 73 High St., Buffalo, NY 14203, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>CPL Associates, LLC, 73 High St., Buffalo, NY 14203</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Crane, John K" sort="Crane, John K" uniqKey="Crane J" first="John K" last="Crane">John K. Crane</name><affiliation wicri:level="2"><nlm:affiliation>Erie County Medical Center, 462 Grider St., Buffalo, NY 14215, USA; University at Buffalo School of Medicine, 326 Biomedical Research Building, 3435 Main St., Buffalo, NY 14214, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Erie County Medical Center, 462 Grider St., Buffalo, NY 14215, USA; University at Buffalo School of Medicine, 326 Biomedical Research Building, 3435 Main St., Buffalo, NY 14214</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Schentag, Jerome J" sort="Schentag, Jerome J" uniqKey="Schentag J" first="Jerome J" last="Schentag">Jerome J. Schentag</name><affiliation wicri:level="2"><nlm:affiliation>University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214, USA; CPL Associates, LLC, 73 High St., Buffalo, NY 14203, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>University at Buffalo School of Pharmacy and Pharmaceutical Sciences, 213 Kapoor Hall, Buffalo, NY 14214, USA; CPL Associates, LLC, 73 High St., Buffalo, NY 14203</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><series><title level="j">International journal of antimicrobial agents</title><idno type="eISSN">1872-7913</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Bacteremia (drug therapy)</term><term>Bacteremia (microbiology)</term><term>Bacteremia (prevention & control)</term><term>Case-Control Studies</term><term>Cephalosporins (therapeutic use)</term><term>Demography</term><term>Disease Eradication</term><term>Female</term><term>Glycopeptides (therapeutic use)</term><term>Humans</term><term>Male</term><term>Methicillin-Resistant Staphylococcus aureus (drug effects)</term><term>Microbial Sensitivity Tests</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Staphylococcal Infections (drug therapy)</term><term>Staphylococcal Infections (microbiology)</term><term>Staphylococcal Infections (prevention & control)</term><term>Time Factors</term><term>Treatment Failure</term><term>Vancomycin (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Antibactériens (usage thérapeutique)</term><term>Bactériémie ()</term><term>Bactériémie (microbiologie)</term><term>Bactériémie (traitement médicamenteux)</term><term>Céphalosporines (usage thérapeutique)</term><term>Démographie</term><term>Facteurs temps</term><term>Femelle</term><term>Glycopeptides (usage thérapeutique)</term><term>Humains</term><term>Infections à staphylocoques ()</term><term>Infections à staphylocoques (microbiologie)</term><term>Infections à staphylocoques (traitement médicamenteux)</term><term>Mâle</term><term>Staphylococcus aureus résistant à la méticilline ()</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tests de sensibilité microbienne</term><term>Vancomycine (usage thérapeutique)</term><term>Échec thérapeutique</term><term>Éradication de maladie</term><term>Études cas-témoins</term><term>Études rétrospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Cephalosporins</term><term>Glycopeptides</term><term>Vancomycin</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Methicillin-Resistant Staphylococcus aureus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bacteremia</term><term>Staphylococcal Infections</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Bactériémie</term><term>Infections à staphylocoques</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Bacteremia</term><term>Staphylococcal Infections</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Bacteremia</term><term>Staphylococcal Infections</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Bactériémie</term><term>Infections à staphylocoques</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibactériens</term><term>Céphalosporines</term><term>Glycopeptides</term><term>Vancomycine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Demography</term><term>Disease Eradication</term><term>Female</term><term>Humans</term><term>Male</term><term>Microbial Sensitivity Tests</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Time Factors</term><term>Treatment Failure</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Bactériémie</term><term>Démographie</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Infections à staphylocoques</term><term>Mâle</term><term>Staphylococcus aureus résistant à la méticilline</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Tests de sensibilité microbienne</term><term>Échec thérapeutique</term><term>Éradication de maladie</term><term>Études cas-témoins</term><term>Études rétrospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Elevated minimum inhibitory concentrations (MICs) of vancomycin against meticillin-resistant Staphylococcus aureus (MRSA) and the emergence of heteroresistant S. aureus strains have led to increased use of anti-MRSA antibiotics other than vancomycin. Ceftaroline fosamil is a novel cephalosporin with activity against MRSA, but there are limited clinical data on its use for MRSA bacteraemia (MRSAB) and against strains exhibiting high vancomycin MICs (2-4 μg/mL). This multicentre, retrospective, case-control study compared the microbiological and clinical effectiveness of ceftaroline used after vancomycin failure with that of vancomycin-treated controls for the treatment of MRSA with vancomycin MICs ≥ 2 μg/mL. In total, 32 patients were matched 1:1 with respect to vancomycin MIC, age and origin of bacteraemia. In the ceftaroline group, patients received prior MRSA therapy for a median of 5 days [interquartile range (IQR), 3-15.8 days] prior to switching to ceftaroline. Median time to eradication of MRSA was significantly less after treatment with ceftaroline compared with vancomycin [4 days (IQR, 3-7.5 days) vs. 8 days (IQR, 5.8-19.5 days); P=0.02]. Both clinical success at the end of treatment and recurrence of MRSA at Day 7 were trending towards being inferior in the vancomycin group, although the results did not attain statistical significance [81% vs. 44% (P=0.06) and 6% vs. 38% (P=0.08), respectively]. Ceftaroline added at the point of vancomycin failure resolves MRSAB more rapidly and with a higher rate of clinical success, therefore ceftaroline should be considered as an alternative for these difficult-to-treat infections.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Oregon</li><li>Pennsylvanie</li><li>État de New York</li></region><settlement><li>Pittsburgh</li></settlement><orgName><li>Université de Pittsburgh</li></orgName></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Paladino, Joseph A" sort="Paladino, Joseph A" uniqKey="Paladino J" first="Joseph A" last="Paladino">Joseph A. Paladino</name></region><name sortKey="Adelman, Martin H" sort="Adelman, Martin H" uniqKey="Adelman M" first="Martin H" last="Adelman">Martin H. Adelman</name><name sortKey="Bader, Justin" sort="Bader, Justin" uniqKey="Bader J" first="Justin" last="Bader">Justin Bader</name><name sortKey="Crane, John K" sort="Crane, John K" uniqKey="Crane J" first="John K" last="Crane">John K. Crane</name><name sortKey="Jacobs, David M" sort="Jacobs, David M" uniqKey="Jacobs D" first="David M" last="Jacobs">David M. Jacobs</name><name sortKey="Schentag, Jerome J" sort="Schentag, Jerome J" uniqKey="Schentag J" first="Jerome J" last="Schentag">Jerome J. Schentag</name><name sortKey="Shields, Ryan K" sort="Shields, Ryan K" uniqKey="Shields R" first="Ryan K" last="Shields">Ryan K. Shields</name><name sortKey="Taylor, Jerusha" sort="Taylor, Jerusha" uniqKey="Taylor J" first="Jerusha" last="Taylor">Jerusha Taylor</name><name sortKey="Wilton, Greg J" sort="Wilton, Greg J" uniqKey="Wilton G" first="Greg J" last="Wilton">Greg J. Wilton</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000970 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000970 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:25282169
|texte= Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:25282169" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PittsburghV1
| This area was generated with Dilib version V0.6.38. |  |